Vaccines, Blood & Biologics
RiaSTAP
Proper Name: Fibrinogen Concentrate (Human)
Tradename: RiaSTAP
Manufacturer: CSL Behring GmbH, License # 1765
- Package insert (PDF, 220 KB) - January 2009
Date: January 16, 2009
Indication: For the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency (afibrinogenemia and hypofibrinogenemia).
January 16, 2009 Approval Letter
Press Release: FDA Approves RiaSTAP for Treatment of Bleeding in Patients with Rare Genetic Defect - January 16, 2009
Summary Basis for Regulatory Action (PDF - 689 KB)
Approval History, Letters, Reviews, and Related Documents
Contact Us
Consumer Affairs Branch (CBER)
- (800) 835-4709
- (301) 827-1800
- ocod@fda.hhs.gov
Division of Communication and Consumer Affairs
Office of Communication, Outreach and Development
Food and Drug Administration
1401 Rockville Pike
Suite 200N/HFM-47
Rockville, MD 20852-1448